María del Pilar
Herrera Puente
Profesor/a Asociado/a en CC. de la Salud
Universidad Complutense de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Universidad Complutense de Madrid (10)
2023
2022
-
Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC
Transplantation and Cellular Therapy, Vol. 28, Núm. 4, pp. 204.e1-204.e10
2021
-
Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant
Frontiers in Immunology, Vol. 12
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
-
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial
Cancers, Vol. 13, Núm. 10
2020
-
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study
Journal of Hematology and Oncology, Vol. 13, Núm. 1
-
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity
British Journal of Haematology, Vol. 189, Núm. 4, pp. 672-683
2019
-
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
Haematologica, Vol. 104, Núm. 2, pp. 288-296
2018
-
Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes
European Journal of Haematology, Vol. 101, Núm. 3, pp. 332-339
2017
-
Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML
Bone Marrow Transplantation, Vol. 52, Núm. 8, pp. 1138-1143